AZNCF ASTRAZENECA PLC
- 154.610
- -0.650-0.42%
ASTRAZENECA PLC News
UPDATE 1-AstraZeneca Plans to Build $1.5 Bln Manufacturing Facility in Singapore
AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial
AstraZeneca (AZN) said Thursday that its investigational long-acting antibody sipavibart showed potential in preventing COVID-19 in immunocompromised patients in a phase 3 trial. The company said the
AstraZeneca's Antibody Cuts COVID-19 Risk Among Immunocompromised in Late-stage Study
AstraZeneca (AZN.L, AZN.ST) said Thursday its investigational long-acting antibody sipavibart showed a significant reduction in the incidence of symptomatic COVID‐19 among immunocompromised people during a late-stage trial.
Pfizer, AstraZeneca, Morgan Stanley Pledge Investments, Jobs to France
Pfizer (PFE), AstraZeneca (AZN), and Morgan Stanley (MS) on Sunday have committed jobs and investments for France ahead of a key foreign investment summit, media reports said.
AstraZeneca Pledges $388 Million Investment at French Site
AstraZeneca (AZN.L, AZN.ST) plans to invest $388 million at its site in Dunkirk, France, Reuters reported Sunday, citing a company announcement.
AstraZeneca Secures 44% Stake in French Biotech Cellectis
AstraZeneca (AZN.L, AZN.ST) said Monday it completed its equity investment in Cellectis (ALCLS.PA) and secured a 44% stake in the clinical-stage French biotechnology company.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study
AstraZeneca (AZN.L, AZN.ST) on Thursday said Calquence combined with chemoimmunotherapy helped improve the progression-free survival of previously untreated adults with mantle cell lymphoma in the Echo phase 3 trial.
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
Astrazeneca on Track for Record High Close -- Data Talk
Astrazeneca PLC Sponsored ADR (AZN) is currently at $76.15, up $0.98 or 1.3% --Would be new all-time high (Based on available data back to May 12, 1993) --Would be the first record close since April
AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
Press Release: Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Canada NewsWire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, Apr
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $5 to $86,
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Trending Tickers: Microsoft, Google, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's
Alphabet, Microsoft, Southwest Earnings: What to Watch
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease
AstraZeneca (AZN.L, AZN.ST) said Tuesday the European Commission approved its Voydeya as an add-on medication for the treatment of the rare blood disease paroxysmal nocturnal hemoglobinuria.
With 85% Ownership, AstraZeneca PLC (LON:AZN) Boasts of Strong Institutional Backing
Astrazeneca (AZN) Could Be a Great Choice
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD). Tezspire is a re
Analysis
Price Target
No Data
